- Susan Blalock has been named to the Food and Drug Administration’s Risk Communication Advisory Committee.
- The appointment runs from 2013 to 2017.
- The committee advises the FDA commissioner on ways of communicating the risks associated FDA-regulated products.
Susan Blalock, MPH, PhD, has been appointed to the Food and Drug Administration’s Risk Communication Advisory Committee. Her term will run through 2017.
Blalock is a professor in the Division of Pharmaceutical Outcomes and Policy and vice chair of the division.
The fifteen-member committee helps ensure that drugs and other products regulated by the FDA are safe and effective. The committee advises the commissioner of the FDA on ways to communicate the risks that are associated with products the agency regulates.
Blalock is a behavioral scientist with expertise in the area of patient and public health education and is particularly interested in risk communication and the impact of pharmaceutical care, including patient education and counseling, on patient health outcomes. Her research focuses primarily on the prevention and treatment of rheumatoid arthritis, osteoarthritis, and osteoporosis. Her current work includes studies evaluating the impact of community-pharmacy based illness prevention and disease management programs.